UPDATE

Sterigenics rebrands, ups E&L services with Toxikon Europe buy

By Flora Southey contact

- Last updated on GMT

GettyImages/pichet_w
GettyImages/pichet_w

Related tags: Medicine

Sotera Health – the recently rebranded Sterigenics International – will add extractables and leachables testing services to its Nelson Labs business with the acquisition of Toxikon Europe NV.

Under the agreement, contract sterilisation services provider Sotera Health will purchase preclinical contract research organisation (CRO) Toxikon Europe – a division of Toxikon Corporation – in a deal that incorporates all staff and a Belgian facility.

“Toxikon Europe NV has approximately 100 employees and has a state-of-the-art laboratory at their headquarters in Leuven, Belgium, all of which will become part of our Nelson Labs business unit,” ​a Sotera Health spokesperson told us.

The deal also covers a long-term supply agreement under which Nelson Labs will outsource in-vivo ​biocompatibility services to Toxikon USA.

“Nelson Labs will now offer Toxikon Europe’s leading extractables and leachables (E&L) capabilities to its customers around the world and in kind, offer Nelson Labs leading microbiological services to Toxikon Europe’s customers,” ​Sotera Health added.

The Sotera Health spokesperson told us Nelson Labs customers had requested E&L services.

“E&L services are becoming more and more important for our customers and regulatory authorities like FDA ​[the US Food and Drug Administration] in testing medical devices and pharmaceutical products.”

Sotera Health expects the acquisition to attract new business, said the firm.

“This acquisition expands the breadth of our laboratory capabilities specifically in extractables and leachables and analytical chemistry,” ​the spokesperson said.

“E&L and analytical chemistry capabilities are critical to the pharmaceutical industry and will allow us to better serve our current pharma customers and attract greater pharma business,” ​she added.

The firms did not disclose financial terms of the deal.

Related topics: Bio Developments

Related news

Follow us

Products

View more

Webinars